The efficacy of Nano calcium in improving bone health

Comparing the Efficacy of Nano Calcium and Marketed Calcium Supplements in Improving Bone Health in Osteopenia Population : A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201401131414N31

Enrollment

Registered

2014-02-22

Start date

2014-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteopenia. Disorders of Bone Density and Structure, Unspecified

Interventions

Intervention 1: Marketing Carbonate Calcium with 500 mg, 2 times daily , 3-month use . Intervention 2: AceNano Calcium with 72 mg Carbonate Calcium Elemental, 3 times daily, 3-month use.

Treatment - Drugs

Marketing Carbonate Calcium with 500 mg, 2 times daily , 3-month use .

AceNano Calcium with 72 mg Carbonate Calcium Elemental, 3 times daily, 3-month use

Eligibility

Sex/Gender

All

Age

45 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion: Osteopenia with T-Score -1 and -2.5; both male and female; Age between 45 to 70 Exclusion: Presence of any systemic or chronic illness such as: Chronic hepatic diseases, Clinically complicated pulmonary, cardiac, hematologic, gastrointestinal, Serious psychological problems such as severe anxiety or depression, Any diagnosed malignancy, A history of active inflammatory illness, Breast feeding, pregnancy or intention to become pregnant during the study period (female patients), Any drug hypersensitivity, Radiotherapy, Chemotherapy or any immunosuppressive drug use, Use of another investigational agent within 6 months of the screening visit, History of kidney stone, hyperparathyroidism or sarcoidosis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Osteocalcin. Timepoint: befor and after intervention. Method of measurement: photometery.	—

Secondary

Measure	Time frame
Serum level of Vitamin D. Timepoint: before and after intervention. Method of measurement: ELISA.;PTH. Timepoint: before and after intervention. Method of measurement: ELISA.;Serum Alkalinphosphatase. Timepoint: before and after intervention. Method of measurement: photometery.;Alb. Timepoint: before and after intervention. Method of measurement: photometery.;Protein. Timepoint: before and after intervention. Method of measurement: photometery.;Cr. Timepoint: before and after intervention. Method of measurement: photometery.;Calcium. Timepoint: before and after intervention. Method of measurement: photometery.;Phosphate. Timepoint: before and after intervention. Method of measurement: photometery.	—

Measure

Time frame

Serum level of Vitamin D. Timepoint: before and after intervention. Method of measurement: ELISA.;PTH. Timepoint: before and after intervention. Method of measurement: ELISA.;Serum Alkalinphosphatase. Timepoint: before and after intervention. Method of measurement: photometery.;Alb. Timepoint: before and after intervention. Method of measurement: photometery.;Protein. Timepoint: before and after intervention. Method of measurement: photometery.;Cr. Timepoint: before and after intervention. Method of measurement: photometery.;Calcium. Timepoint: before and after intervention. Method of measurement: photometery.;Phosphate. Timepoint: before and after intervention. Method of measurement: photometery.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026